AU2020296620B2 — Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
Assigned to Oncobix CoLtd · Expires 2023-07-13 · 3y expired
What this patent protects
The present invention provides a novel pyrimidine derivative compound and a pharmaceutically acceptable salt thereof, each of which inhibits the growth of cancer cells. The present invention provides a pharmaceutical composition comprising the compound or a pharmaceutically accep…
USPTO Abstract
The present invention provides a novel pyrimidine derivative compound and a pharmaceutically acceptable salt thereof, each of which inhibits the growth of cancer cells. The present invention provides a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof. The present invention also provides a medicinal use of the pyrimidine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of lung cancer. In addition, the present invention provides a method for treatment of lung cancer, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition comprising same to a subject in need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.